RxDoctor Payments DataLook up a doctor →

Kyle Smoot, MD

Neurology · Portland, ORNPI 1124170063

Payments from drug & device makers

$3,192,773in general payments, 2019–2025

Across 1,150 payments — averaging $2776.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech, Inc.$598K
  • AbbVie$588K
  • Sanofi$585K
  • EMD Serono, Inc.$490K
  • Biogen$416K
  • TG Therapeutics, Inc.$208K
  • plus $308K from 10 others
$1,088in research payments, 2019–2025

Across 13 payments — averaging $83.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$1K
  • Biogen$16

What the payments were for

  • Consulting fees$109,25212%
  • Speaking & faculty fees$696,72475%
  • Travel & lodging$105,48711%
  • Food & beverage$20,1032%
  • Education$3930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,192,773 in reported general payments places this provider in the 95th percentile of 228 neurology providers in Oregon.

See all neurology providers in Oregon

Medicare billing

Part B allowed, 2024
$32,389
Medicare patients
141
Services billed
354

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab92$800,544
CopaxoneGlatiramer Acetate36$194,882
Avonex (4 Pack)Interferon Beta-1a20$169,435
Avonex Pen (4 Pack)Interferon Beta-1a13$133,929
MayzentSiponimod12$112,037
VumerityDiroximel Fumarate13$100,111
Aimovig AutoinjectorErenumab-Aooe20$18,933
Dalfampridine ErDalfampridine89$17,449
Nurtec OdtRimegepant Sulfate13$13,041
Modafinil119$11,620
Baclofen385$11,434
Dimethyl Fumarate61$11,092
Gabapentin221$5,767
Duloxetine Hcl103$2,912
Tizanidine Hcl140$2,537

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
BiogenAvonex (4 Pack), Vumerity$416,215$269,54533 claims
Teva Pharmaceuticals USA, Inc.Copaxone$18$194,88236 claims
NovartisMayzent$134,705$112,03712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 228 neurology providers in Oregon.

Other neurology in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →